Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: A cross-sectional study

Annals of Pharmacotherapy

Volumn 41, Issue 3, 2007, Pages 408-413

  Mulder, Hans ^a,b   Heerdink, Eibert R ^a   Van Iersel, Elsje E ^b   Wilmink, Frederik W ^c   Egberts, Antoine C G ^a,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Wilhelmina Ziekenhuis   (Netherlands)

^c Mental Health Centre Drenthe   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antidepressants; Antipsychotics; Cytochrome P450 2D6

Indexed keywords

ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2D6; ISOENZYME; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG METABOLISM; DRUG TREATMENT FAILURE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DEPRESSION; DRUG UTILIZATION; FEMALE; GENOTYPE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PHARMACOGENETICS;

EID: 34047221919     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H482     Document Type: Article

References (27)

1. Wolf CR, Smith NL, Smith G. Pharmacogenetics. BMJ 2000:320;987-90.
2. Kirchheiner J, Fuhr U, Brockmoller J. Pharmacogenetics-based therapeutic recommendations-ready for clinical practice? Natl Rev Drug Discov 2005;4:639-47.
3. De Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006;47:75-85.
4. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5:6-13.
5. Gardiner SJ, Begg EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics 2005;15:365-9.
6. Tamminga WJ, Wemer J, Oosterhuis B, et al. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study. Eur J Clin Pharmacol 2003;59:57-64.
7. Davies SJ, Eayrs S, Pratt P, Lennard MS. Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol 2004;57:464-72.
8. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9:442-3.
9. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 2000
10. Drug interaction table. Indiana University Department of Medicine. http://medicine.iupui.edu/flockhart/table.htm (accessed 2006 May 16).
11. Mulder H, Wilmink FW, Beumer TL, Tamminga WJ, Jedema JN, Egberts AC. The association between cytochrome P450 2D6 genotype and prescription patterns of antipsychotic and antidepressant drugs in hospitalized psychiatric patients: a retrospective follow-up study. J Clin Psychopharmacol 2005;25:188-91.
12. Brockmoller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002;72:438-52.
13. Mulder H, Herder A, Wilmink FW, Tamminga WJ, Belitser SV, Egberts AC. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice. Pharmacoepidemiol Drug Saf 2006;15:107-14.
14. Bazire S. Psychotropic drug directory 2002. Bath, England: Mark Allen Publishing Ltd., 2001.
15. Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M. Metabolic drug interactions. Philadelphia, Lippincott Williams & Wilkins, 2000.
16. Genemedrix: drug-drug and drug-gene interaction software, www.genemedrx.com (accessed 2006 Dec 4).
17. Grasmader K, Verwohlt PL, Kuhn KU, et al. Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol 2004;60:473-80.
18. Desta Z, Wu GM, Morocho AM, Flockhart DA. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos 2002;30:336-43.
19. Nakamura K, Yokoi T, Inoue K, et al. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. Pharmacogenetics 1996;6:449-57.
20. Kirchheiner J, Henckel HB, Meineke I, Roots I, Brockmoller J. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol 2004;24:647-52.
21. Jaanson P, Marandi T, Kiivet RA, et al. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (Berl) 2002;162:67-73.
22. Brynne N, Dalen P, Alvan G, Bertilsson L, Gabrielsson J. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clin Pharmacol Ther 1998;63:529-39.
23. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy, the past, present and future. Trends Pharmacol Sci 2004;25:193-200.
24. Ozdemir V, Kalow W, Tothfalusi L, Bertilsson L, Endrenyi L, Graham JE. Multigenic control of drug response and regulatory decision-making in pharmacogenomics: the need for an upper-bound estimate of genetic contributions. Curr Pharmacogenom 2005;3:53-71.
25. Dugan SE, Fuller MA. Duloxetine: a dual reuptake inhibitor. Ann Pharmacother 2004;38:2078-85. Epub 2 Nov 2004. DOI 10.1345/aph.1E084
26. Eiland LS, Guest AL. Atomoxetine treatment of attention-deficit/ hyperactivity disorder. Ann Pharmacother 2004;38:86-90. DOI 10.1345/aph.1D144
27. Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother 2003;37:687-94. DOI 10.1345/aph.1C297